Abstract
We evaluated growth in 49 children (34 males) diagnosed with HD at mean age of 8.4 yrs (2.4-11.8 yrs). Pts were treated with: radiation (RT) only, 13 pts; chemotherapy (CT) only, 8 pts; combination CT + RT, 29 pts. CT consisted of Cyclophosphamide, Adriamycin, Vincristine, Procarbazine and Prednisone. Mean RT dose was 30 Cy (0.2-51). Six of 41 irradiated pts received total lymphoid irradiation (TLI), 2l mantle, and 14 only involved field. Ht was obtained at diagnosis, at end of Rx (0.5 yr for RT only, 1-1.5 yrs for CT±RT), 1, 2, 3 yrs post-Rx, and at attainment of final ht. The mean change (A) in ht z-score for CT, CT+RT, and RT are, respectively: −0.45, −0.36, 0.06 at end of Rx; −0.60, −0.46, 0.06 1 yr post-Rx; −0.37, −0.44, −0.05 2 yr post-Rx; −0.29, −0.38, 0.01 3 yr post-Rx; 0.15 (2 Pts), −0.79 (16 Pts), −0.68 (6 Pts) final ht (fig). Ht decreased significantly at end of Rx for CT (p=0.008) and CT+RT (p=0.0002) but not for RT alone (p=0.26). There was a trend for continued reduction in ht z-score between end of Rx and final ht for RT and CT+RT. Change in ht z-score did not correlate with age at diagnosis, sex, or stage of disease. We conclude that children Rx'ed for HD with CT+RT experience a modest but significant loss in ht z-score, that appears to be permanent in those Rx'ed with CT+RT.
Article PDF
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Papadakis, V., Tan, C. & Sklar, C. GROWTH AND FINAL HEIGHT (Ht) AFTER TREATMENT (Rx) FOR HODGKIN'S DISEASE (HD). Pediatr Res 33 (Suppl 5), S51 (1993). https://doi.org/10.1203/00006450-199305001-00287
Issue Date:
DOI: https://doi.org/10.1203/00006450-199305001-00287